In the last trading session, 1.78 million Tarsus Pharmaceuticals Inc (NASDAQ:TARS) shares changed hands as the company’s beta touched 1.05. With the company’s per share price at $41.29 changed hands at -$4.25 or -9.33% during last session, the market valuation stood at $1.58B. TARS’s last price was a discount, traded about -38.73% off its 52-week high of $57.28. The share price had its 52-week low at $20.08, which suggests the last value was 51.37% up since then.
Analysts gave the Tarsus Pharmaceuticals Inc (TARS) stock a consensus recommendation rating of Buy, calculated at a mean rating of 1.38. If we narrow down to specifics, the data shows that 0 out of 4 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 0 recommended TARS as a Hold, 4 felt it is a Buy and 0 rated the stock as Underweight. Tarsus Pharmaceuticals Inc’s EPS for the current quarter is expected to be -0.77.
Tarsus Pharmaceuticals Inc (NASDAQ:TARS) trade information
Instantly TARS was in red as seen at the end of in last trading. With action -18.80%, the performance over the past five days has been red. The company’s shares are showing year-to-date downside of -25.43%, with the 5-day performance at -18.80% in the red. However, in the 30-day time frame, Tarsus Pharmaceuticals Inc (NASDAQ:TARS) is -15.35% down.
The consensus price target for the stock as assigned by Wall Street analysts is 67, meaning bulls need an upside of 38.37% from its current market value. According to analyst projections, TARS’s forecast low is 62 with 72 as the target high. To hit the forecast high, the stock’s price needs a -74.38% plunge from its current level, while the stock would need to soar -50.16% for it to hit the projected low.
Tarsus Pharmaceuticals Inc (TARS) estimates and forecasts
Year-over-year growth is forecast to reach 88.72% up from the last financial year.
Consensus estimates given by 3 financial analysts project the company’s revenue in the current quarter to hit an average of 66.85M. 3 analysts are of the opinion that Tarsus Pharmaceuticals Inc’s revenue for the current quarter will be 84.25M. The company’s revenue for the corresponding quarters a year ago was 27.61M and 40.81M respectively. According to analysts, the company will likely register a growth in its current quarter sales, forecast at 142.09%. The estimates for the next quarter sales put growth at 106.44%.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of -132.82%. The 2025 estimates are for Tarsus Pharmaceuticals Inc earnings to increase by 31.10%.
TARS Dividends
Tarsus Pharmaceuticals Inc is expected to release its next quarterly earnings report in March.
RTW INVESTMENTS, LP holds the second largest percentage of outstanding shares, with 9.0222% or 3.41 million shares worth $92.75 million as of 2024-06-30.
Among Mutual Funds, the top two as of Sep 30, 2024 were Vanguard Total Stock Market Index Fund and iShares Russell 2000 ETF . With 1.14 shares estimated at $46.88 million under it, the former controlled 2.97% of total outstanding shares. On the other hand, iShares Russell 2000 ETF held about 2.70% of the shares, roughly 1.03 shares worth around $42.58 million.
